6.5 C
New York
Wednesday, October 20, 2021

Novavax claims its COVID vaccine is more than 90% effective against variants of concern

Must Read

Will the Indian stock market soon overtake London?

Nothing could stop the Indian stock market for the past year and a half.

A popular vitamin supplement that increases Dementia risk – experts warn

Dementia is sometimes viewed as a death sentence due to the lack of a cure and the...

FDA: Lupin recalls two blood pressure drugs after finding cancer-causing substance

Two blood pressure drugs are being recalled for possibly containing high levels of N-nitrosoirbesartan - a substance...
Kamal Saini
Kamal S. has been Journalist and Writer for Business, Hardware and Gadgets at Revyuh.com since 2018. He deals with B2b, Funding, Blockchain, Law, IT security, privacy, surveillance, digital self-defense and network policy. As part of his studies of political science, sociology and law, he researched the impact of technology on human coexistence. Email: kamal (at) revyuh (dot) com

The two-dose vaccine has been shown to be 100% effective in preventing moderate to severe disease and 93% effective against some variants of concern.

The biotechnology firm said on June 14 that its COVID-19 vaccine is 90.4% safe and effective. 

These data were obtained during the third phase of a clinical trial involving nearly 30,000 participants from the United States and Mexico.

The two-dose vaccine has been shown to be 100% effective in preventing moderate to severe disease and 93% effective against some variants, Novavax said. The company said it plans to apply to the Food and Drug Administration in the third quarter of this year.

The late-stage trial “confirms that NVX-CoV2373 offers an encouraging tolerability and safety profile,” said Dr. Gregory Glenn, president of research and development at Novavax, in a press release.

“These data show consistent, high levels of efficacy and reaffirm the ability of the vaccine to prevent COVID-19 amid ongoing genetic evolution of the virus.”

The study assessed 77 confirmed COVID infections among 29,960 study participants. Novavax noted that the placebo group observed 63 cases of coronavirus against 14 cases in the group receiving two doses of the vaccine. This led to an estimate of the effectiveness of the vaccine at 90.4%.

According to the company, the vaccine is well tolerated. The most common side effects were fatigue, headache, muscle pain, and pain at the injection site, which usually lasted no more than two to three days.

All COVID hospitalizations during the trial occurred in the placebo group, the company said.

Novavax said the vaccine was effective against some variant, including the Alpha variant, first discovered in the UK. About 65% of the cases included were “variants of concern,” the company said.

It was previously reported that seven people in Japan develop heart complications after the second dose of the Pfizer vaccine

Photo by Karen Ducey/Getty Images

- Advertisement -
- Advertisement -

Latest News

- Advertisement -

More Articles Like This

- Advertisement -